Browse by Phase
Phase 3 Clinical Trials
Phase 3 trials compare a new drug or treatment against the current standard of care in a large population (300–3,000+ participants). Successful Phase 3 results are the basis for regulatory approval.
Total Trials
537
Recruiting Now
537
Top Conditions in Phase 3
Frequently Asked Questions — Phase 3 Trials
Why are Phase 3 trials the standard for drug approval?
Phase 3 trials compare a new treatment against the current standard of care in a large, randomized population of 300–3,000+ participants. This large-scale comparative evidence is what regulatory agencies—FDA, EMA—require to approve a new drug. A successful Phase 3 trial demonstrates that the new treatment is more effective, safer, or both compared to existing options in a statistically significant, reproducible way.
What is a placebo control in a Phase 3 trial?
Many Phase 3 trials use a placebo control—a group that receives an inactive substance—to isolate the true effect of the treatment. When an established standard of care exists, control-arm participants typically receive that treatment rather than a placebo, for ethical reasons. Blinded designs prevent participants and investigators from knowing who received which treatment, reducing bias in outcome assessment.
How do I find and join a Phase 3 clinical trial?
ClinicalMetric lists all Phase 3 trials registered on ClinicalTrials.gov. Each trial card shows recruitment status, enrollment target, sponsor, conditions studied, and site locations. To join a Phase 3 trial, review the eligibility criteria and contact the trial site directly—usually an academic medical center or hospital. Your physician can facilitate a referral to the appropriate study site.
Active Phase 3 Studies
NCT07168200 Phase 3
Recruiting
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiothe...
Condition
Advanced Cervical Cancer
Enrollment
720 pts
Location
China
Sponsor
Shanghai Shengdi Pharmaceutica
NCT07476729 Phase 3
Recruiting
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 202...
Condition
B-Cell Acute Lymphoblastic Leukaemia
Enrollment
750 pts
Location
Austria, Belgium, Czechia
Sponsor
Charite University, Berlin, Ge
NCT06472245 Phase 3
Recruiting
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung...
Condition
Patients With Non-Small Cell Lung Cancer
Enrollment
363 pts
Location
United States, Belgium, Canada
Sponsor
OSE Immunotherapeutics
NCT07792954 Phase 3
Recruiting
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly C...
Condition
Obesity
Enrollment
300 pts
Location
China
Sponsor
Pfizer
NCT06214195 Phase 3
Recruiting
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy ...
Condition
Cardiotoxicity Induced by Drug Therapy for Breast Cancer
Enrollment
276 pts
Location
China
Sponsor
Zhejiang Cancer Hospital
NCT07234695 Phase 3
Recruiting
LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults W...
Condition
Down Syndrome
Enrollment
120 pts
Location
Spain
Sponsor
Fundació Institut de Recerca d
NCT06174922 Phase 3
Recruiting
A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allerg...
Condition
Allergic Bronchopulmonary Aspergillosis
Enrollment
300 pts
Location
India
Sponsor
Post Graduate Institute of Med
NCT06263231 Phase 3
Recruiting
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US...
Condition
Sarcoma,Soft Tissue
Enrollment
333 pts
Location
United States, Canada, France
Sponsor
Intensity Therapeutics, Inc.
NCT07047456 Phase 3
Recruiting
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malign...
Condition
Acute Graft Versus Host Disease
Enrollment
134 pts
Location
China
Sponsor
Anhui Provincial Hospital
NCT06791005 Phase 3
Recruiting
A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patie...
Condition
Papillary Thyroid Cancer
Enrollment
400 pts
Location
China
Sponsor
Second Affiliated Hospital of
NCT05654922 Phase 3
Recruiting
Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progress...
Condition
Pre-Bronchiolitis Obliterans Syndrome
Enrollment
100 pts
Location
United States
Sponsor
Renovion, Inc.
NCT06677970 Phase 3
Recruiting
Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Press...
Condition
Acute Ischemic Stroke
Enrollment
176 pts
Location
South Korea
Sponsor
Yonsei University
NCT05199194 Phase 3
Recruiting
Randomization to Endovascular Treatment Alone or Preceded by Systemic Thrombolys...
Condition
Stroke, Ischemic
Enrollment
398 pts
Location
Brazil
Sponsor
Hospital Moinhos de Vento
NCT05357846 Phase 3
Recruiting
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Loca...
Condition
Squamous Cell Esophageal Carcinoma
Enrollment
422 pts
Location
China
Sponsor
Sun Yat-sen University
NCT06742996 Phase 3
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib ...
Condition
Mantle Cell Lymphoma
Enrollment
300 pts
Location
United States, Argentina, Australia
Sponsor
BeOne Medicines
NCT05400317 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of AD-218
Condition
Mixed Dyslipidemia
Enrollment
520 pts
Location
South Korea
Sponsor
Addpharma Inc.
NCT06658197 Phase 3
Recruiting
Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute L...
Condition
Stroke, Ischemic
Enrollment
850 pts
Location
China
Sponsor
Xuanwu Hospital, Beijing
NCT05844462 Phase 3
Recruiting
Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary...
Condition
Pulmonary Hypertension
Enrollment
200 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux
NCT07151703 Phase 3
Recruiting
Topical Versus Injection PRP for Olfactory Dysfunction
Condition
Olfactory Dysfunction
Enrollment
60 pts
Location
Taiwan
Sponsor
Taipei Veterans General Hospit
NCT05132439 Phase 3
Recruiting
MetfOrmin BenefIts Lower Extremities With Intermittent Claudication
Condition
Intermittent Claudication
Enrollment
200 pts
Location
United States
Sponsor
VA Office of Research and Deve
NCT04062565 Phase 3
Recruiting
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vasc...
Condition
Pulmonary Arterial Hypertension
Enrollment
20 pts
Location
United States
Sponsor
University of Arizona
NCT05841056 Phase 3
Recruiting
Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Pati...
Condition
Atrial Fibrillation New Onset
Enrollment
400 pts
Location
Canada
Sponsor
Population Health Research Ins
NCT06250972 Phase 3
Recruiting
Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer
Condition
Pancreatic Adenocarcinoma
Enrollment
210 pts
Location
China
Sponsor
Fudan University
NCT07015892 Phase 3
Recruiting
Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase II...
Condition
Small Cell Lung Carcinoma
Enrollment
300 pts
Location
Spain
Sponsor
Instituto de Investigación Bio
NCT03998319 Phase 3
Recruiting
A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) P...
Condition
STEMI
Enrollment
445 pts
Location
Australia, New Zealand
Sponsor
University of Sydney
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology